Keyphrases
Phase II Clinical Trial
100%
Essential Thrombocythemia
100%
Politicians
100%
New Drugs
100%
Cost-effectiveness Model
100%
Cost-effectiveness
80%
Rare Diseases
80%
Pharmaceutical Agents
80%
Economic Model
60%
Anagrelide
60%
Health Care Costs
40%
Clinical Efficacy
40%
Major Complications
40%
Clinical Trials
20%
New Therapies
20%
Megakaryocytes
20%
Therapeutic Outcome
20%
Thrombocytosis
20%
First Year
20%
Myocardial Infarction
20%
Phase II Trial
20%
Sensitivity Analysis
20%
Economic Development
20%
Therapeutic Decision-making
20%
Hemorrhagic Complications
20%
Response Rate
20%
High Cost
20%
New Agents
20%
Unknown Origin
20%
Clinical Costs
20%
Gastrointestinal Bleeding
20%
Transient Ischemic Attack
20%
Primary Therapy
20%
Platelet Count
20%
Thrombotic Complications
20%
Refractory Angina
20%
Platelet Aggregation Inhibitors
20%
Chronic Myeloproliferative Disorders
20%
Transient Ischemic Stroke
20%
Head-to-head Studies
20%
Pharmacology, Toxicology and Pharmaceutical Science
Clinical Trial
100%
Thrombocythemia
100%
Rare Disease
80%
Anagrelide
60%
Thrombocytosis
20%
Bleeding
20%
Heart Infarction
20%
Brain Ischemia
20%
Antithrombocytic Agent
20%
Transient Ischemic Attack
20%
Ciclonicate
20%
Myeloproliferative Disorder
20%
Phase III Trials
20%